241 related articles for article (PubMed ID: 33217017)
1. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
Gautier-Veyret E; Thiebaut-Bertrand A; Roustit M; Bolcato L; Depeisses J; Schacherer M; Schummer G; Fonrose X; Stanke-Labesque F
Br J Clin Pharmacol; 2021 Jun; 87(6):2534-2541. PubMed ID: 33217017
[TBL] [Abstract][Full Text] [Related]
2. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
[TBL] [Abstract][Full Text] [Related]
3. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
5. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
[TBL] [Abstract][Full Text] [Related]
6. Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole.
Jia SJ; Gao KQ; Huang PH; Guo R; Zuo XC; Xia Q; Hu SY; Yu Z; Xie YL
Front Pharmacol; 2021; 12():666296. PubMed ID: 34113252
[No Abstract] [Full Text] [Related]
7. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
9. Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization.
Hao X; Li Y; Zhang Y; Bian J; Zhao J; Zhao Y; Hu L; Luo X; Yang C; Feng Y; Huang L
Br J Clin Pharmacol; 2024 Feb; 90(2):440-451. PubMed ID: 37766511
[TBL] [Abstract][Full Text] [Related]
10. Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection.
Boglione-Kerrien C; Morcet J; Scailteux LM; Bénézit F; Camus C; Mear JB; Gangneux JP; Bellissant E; Tron C; Verdier MC; Lemaitre F
Mycoses; 2023 May; 66(5):396-404. PubMed ID: 36698317
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
[TBL] [Abstract][Full Text] [Related]
13. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
[TBL] [Abstract][Full Text] [Related]
15. Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population.
Li Y; Zhang Y; Zhao J; Bian J; Zhao Y; Hao X; Liu B; Hu L; Liu F; Yang C; Feng Y; Huang L
J Chemother; 2024 May; 36(3):179-189. PubMed ID: 37599449
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis.
Jiang Z; Wei Y; Huang W; Li B; Zhou S; Liao L; Li T; Liang T; Yu X; Li X; Zhou C; Cao C; Liu T
Front Pharmacol; 2022; 13():982981. PubMed ID: 36225581
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X; Zhao J; Wen T; Liao X; Luo B
Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
[TBL] [Abstract][Full Text] [Related]
18. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
19. Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?
Danion F; Jullien V; Rouzaud C; Abdel Fattah M; Lapusan S; Guéry R; Bigé N; Morgand M; Pallet N; Lanternier F; Lortholary O
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967027
[TBL] [Abstract][Full Text] [Related]
20. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
